News

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
Eli Lilly sues telehealth companies for selling Mounjaro, Zepbound compounds
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Eli Lilly stock sell-off was 'overreaction': Analysts
Eli Lilly's stock suffered a nearly 12% loss in markets Thursday despite strong earnings, in what analysts say is an ...
Why Eli Lilly Stock Is Sinking Today
Shares of Eli Lilly ( LLY -10.79%) are sliding on Thursday. The stock lost 8.3% as of 12:21 p.m. ET. The leg down comes as ...
Eli Lilly CEO says tariffs are not the answer, urges Trump to move fast on trade deals
Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.
Lilly cuts earnings guidance on research costs, shares fall
Eli Lilly & Co.’s shares fell 6% early Thursday after the drugmaker cut its full-year earnings outlook citing research costs ...
Eli Lilly stock slips despite earnings beat, reaffirmed 2025 guidance
Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...